FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2340806582> ?p ?o ?g. }

• W2340806582 endingPage "S133" @default.
• W2340806582 startingPage "S133" @default.
• W2340806582 abstract "The performance and treatment profile of advanced EML4-ALK positive Non-small cell lung cancer (NSCLC) patients in a developing country with potentially restricted access to Crizotinib has not been evaluated systematically. We conducted a retrospective analysis of advanced ALK positive NSCLC patients who were treated from June 2012 to September 2015. Baseline characteristics, access to Crizotinib, treatment regimens and survival were noted. The primary goal was to evaluate outcomes of advanced ALK positive NSCLC in our practice and examine the logistic constraints in procuring Crizotinib. 94 patients were available for analysis. Median age was 51 years with 56.4% male patients and 19.1% smokers. 21 (22.3%) patients were started on Crizotinib upfront, 60 (63.8%) on chemotherapy, 10 (10.6%) on Tyrosine kinase inhibitors (in view of poor PS) and 3 (3.2%) patients were offered best supportive care. Common reasons for not starting Crizotinib upfront included symptomatic patients needing early initiation of therapy (23.3%), ALK not tested upfront (23.3%) and financial constraints (21.9%). 69 patients (73.4%) received Crizotinib at some of point of time during treatment. Dose interruptions (> 1 week) with Crizotinib were seen in 20 patients (29%), with drug toxicity being the commonest reason (85%). Median Progression free survival (PFS) on first line therapy for the entire cohort was 10 months (95% Confidence Interval [CI] 6.57–13.43 months), with a significant difference between patients receiving Crizotinib and those who did not ever receive Crizotinib (10 months vs. 2 months, p = 0.028). There was no difference in PFS whether Crizotinib was received upfront or later (12 months vs 10 months, p = 0.159). Patients with an ECOG PS of >2 had a significantly reduced PFS compared to patients with PS ≤2 (1.5 months vs. 11 months, p < 0.001). 47 patients with financial constraints (68.1%) received Crizotinib completely free via various extramural support schemes, while 22 patients (31.9%) availed Crizotinib by their own means. We managed to expose majority of our ALK positive NSCLC patients to Crizotinib through the help of various support mechanisms and these patients had outcomes similar to that reported from Western literature." @default.
• W2340806582 created "2016-06-24" @default.
• W2340806582 creator A5003412464 @default.
• W2340806582 creator A5027531002 @default.
• W2340806582 creator A5031219890 @default.
• W2340806582 creator A5032083634 @default.
• W2340806582 creator A5040085413 @default.
• W2340806582 creator A5050313092 @default.
• W2340806582 creator A5082030725 @default.
• W2340806582 creator A5082818936 @default.
• W2340806582 creator A5089100168 @default.
• W2340806582 creator A5089917090 @default.
• W2340806582 date "2016-04-01" @default.
• W2340806582 modified "2023-09-29" @default.
• W2340806582 title "175P: ALK positive lung cancer: Clinical profile and outcomes in a developing country" @default.
• W2340806582 doi "https://doi.org/10.1016/s1556-0864(16)30285-4" @default.
• W2340806582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27198312" @default.
• W2340806582 hasPublicationYear "2016" @default.
• W2340806582 type Work @default.
• W2340806582 sameAs 2340806582 @default.
• W2340806582 citedByCount "0" @default.
• W2340806582 crossrefType "journal-article" @default.
• W2340806582 hasAuthorship W2340806582A5003412464 @default.
• W2340806582 hasAuthorship W2340806582A5027531002 @default.
• W2340806582 hasAuthorship W2340806582A5031219890 @default.
• W2340806582 hasAuthorship W2340806582A5032083634 @default.
• W2340806582 hasAuthorship W2340806582A5040085413 @default.
• W2340806582 hasAuthorship W2340806582A5050313092 @default.
• W2340806582 hasAuthorship W2340806582A5082030725 @default.
• W2340806582 hasAuthorship W2340806582A5082818936 @default.
• W2340806582 hasAuthorship W2340806582A5089100168 @default.
• W2340806582 hasAuthorship W2340806582A5089917090 @default.
• W2340806582 hasBestOaLocation W23408065821 @default.
• W2340806582 hasConcept C117643217 @default.
• W2340806582 hasConcept C126322002 @default.
• W2340806582 hasConcept C143998085 @default.
• W2340806582 hasConcept C167135981 @default.
• W2340806582 hasConcept C2776232967 @default.
• W2340806582 hasConcept C2776256026 @default.
• W2340806582 hasConcept C2778347629 @default.
• W2340806582 hasConcept C2779422266 @default.
• W2340806582 hasConcept C44249647 @default.
• W2340806582 hasConcept C71924100 @default.
• W2340806582 hasConcept C72563966 @default.
• W2340806582 hasConceptScore W2340806582C117643217 @default.
• W2340806582 hasConceptScore W2340806582C126322002 @default.
• W2340806582 hasConceptScore W2340806582C143998085 @default.
• W2340806582 hasConceptScore W2340806582C167135981 @default.
• W2340806582 hasConceptScore W2340806582C2776232967 @default.
• W2340806582 hasConceptScore W2340806582C2776256026 @default.
• W2340806582 hasConceptScore W2340806582C2778347629 @default.
• W2340806582 hasConceptScore W2340806582C2779422266 @default.
• W2340806582 hasConceptScore W2340806582C44249647 @default.
• W2340806582 hasConceptScore W2340806582C71924100 @default.
• W2340806582 hasConceptScore W2340806582C72563966 @default.
• W2340806582 hasIssue "4" @default.
• W2340806582 hasLocation W23408065821 @default.
• W2340806582 hasOpenAccess W2340806582 @default.
• W2340806582 hasPrimaryLocation W23408065821 @default.
• W2340806582 hasRelatedWork W1957032760 @default.
• W2340806582 hasRelatedWork W2080538788 @default.
• W2340806582 hasRelatedWork W2374768601 @default.
• W2340806582 hasRelatedWork W2516942920 @default.
• W2340806582 hasRelatedWork W2545452342 @default.
• W2340806582 hasRelatedWork W2811223828 @default.
• W2340806582 hasRelatedWork W2951367982 @default.
• W2340806582 hasRelatedWork W3035529108 @default.
• W2340806582 hasRelatedWork W3197633853 @default.
• W2340806582 hasRelatedWork W3199005851 @default.
• W2340806582 hasVolume "11" @default.
• W2340806582 isParatext "false" @default.
• W2340806582 isRetracted "false" @default.
• W2340806582 magId "2340806582" @default.
• W2340806582 workType "article" @default.